 | |  |
Flagship portfolio company Renovis files for IPO
South San Francisco, Calif. - October 17, 2003 - Renovis, a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock.
Goldman, Sachs & Co. is acting as book-runner and lead manager, and CIBC World Markets, SG Cowen and U.S. Bancorp Piper Jaffray are acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A preliminary prospectus for the offering may be obtained when available from Goldman, Sachs & Co.'s prospectus department at 85 Broad Street, New York, New York 10004, by telephone at 212-902-1000 or by faxing a request to 212-902-3000.
About Renovis, Inc.
Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. We are currently pursuing eight distinct programs, including three product candidates in clinical development. Our most advanced product candidate is Cerovive(R), an intravenous drug for acute ischemic stroke that is in Phase III clinical trials with our exclusive licensee, AstraZeneca plc. We are independently developing two clinical candidates for the treatment of pain: REN-1654, an oral drug for neuropathic pain in Phase II clinical trials, and REN-213, an intravenous drug for acute post-operative pain in a Phase I clinical trial. Our research and development programs focus on major medical needs in the areas of pain, trauma and stroke as well as neurodegenerative diseases.
| | |
